SORD2P

Across TCGA pan-cancer cohorts, SORD2P RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated SORD2P data layer.

The strongest signal is observed in mesothelioma (MESO), where higher SORD2P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated SORD2P expression acts as an unfavorable survival marker, although some lineages such as LIHC and LGG show a favorable association.

MESO, ACC, and SKCM are the cancer types where SORD2P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	IV	0.244	0.770	<.001	55	view →
ACC	OS	Median	II,III,IV	0.373	0.769	<.001	53	view →
SKCM	DFS	Median	II,III,IV	0.614	0.796	.003	46	view →
UVM	OS	Quartile	III,IV	0.318	0.900	.007	36	view →
LIHC	OS	Quartile	III,IV	0.868	0.192	<.001	31	view →
LGG	OS	Tertile	All	0.582	0.408	<.001	28	view →
COAD	OS	Quartile	II,III,IV	0.658	0.920	<.001	27	view →
READ	DFS	Tertile	III,IV	0.724	0.357	.002	25	view →
KIRP	DFS	Quartile	All	0.877	0.986	.001	24	view →
UCEC	DFS	Median	IV	0.634	0.266	.013	24	view →
OV	OS	Quartile	III,IV	0.249	0.362	.018	22	view →
LUAD	OS	Quartile	All	0.767	0.905	<.001	21	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

SORD2P–MESO (OS)

Open the MESO breakdown →